IceCure jumps after FDA-cleared breast tumor treatment gains traction in US
17/06/2026 13:58
BUZZ-IceCure jumps after FDA-cleared breast tumor treatment gains traction in US ** Shares of Israel-based medical device maker IceCure Medical ICCM.O more than triple to $6.77 premarket
** Demand for ProSense system surges in U.S. after FDA cleared breast cancer treatment in October 2025
** ProSense system uses extreme cold to destroy tumors, offering alternative for older patients unfit for surgery
** Installations of the system at U.S. sites jumped 70% since clearance, with procedures across major cities
** Updated doctors’ guidelines, higher patient awareness and media coverage boosted adoption
** Interest from physicians rose sharply at medical conferences vs 2025, supporting sales pipeline - ICCM
** As of last close, stock down ~88% YTD
(Reporting by Sahil Pandey in Bengaluru)
Recent news on Icecure Medical
See all newsIcecure Medical Ltd reports results for the quarter ended June 30 - Earnings Summary
Israel's IceCure Medical H1 revenue rises on higher system, probe sales
Brief: Icecure Sio Petitions Nccn To Include Cryoablation In Breast Cancer Treatment Guidelines, Citing Icecure's FDA Clearance Of Prosense®
NASDAQ RESUMED AT 09:55 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:45 AM